Cassava Sciences | PTIE - Actif À Court Terme





Actif À Court Terme Changement Date
Abbott USD 23.5B 1.02B 2026-09
Amgen USD 34.36B 598M 2026-09
Biogen USD 7.58B 278.7M 2026-09
Cara Therapeutics USD 25.33M 6.21M 2026-03
Cassava Sciences USD 80.06M 3.67M 2026-09
Eisai JPY 883.01B 121.38B 2026-06
Eli Lilly USD 65.26B 591M 2026-09
Geron USD 468.74M 17.6M 2026-09
J&J USD 56.35B 3.42B 2026-09
Merck USD 38.94B 2.26B 2026-09
Novartis USD 28.75B 1.4B 2026-09
Novavax USD 707.96M 63.14M 2026-09
Pfizer USD 45.01B 3.65B 2026-09
Roche Holding CHF 35.44B 3.29B 2026-06